Sotatercept
Sotatercept, sold as Winrevair, is an activin signaling inhibitor. The US label lists treating adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and World Health Organization functional class, and to reduce the risk of clinical worsening events. The label describes it as a recombinant activin receptor type IIA-Fc fusion protein. It is filed under the class page for activin signaling inhibitors, of which it is the only member.
Also called Winrevair · Sotatercept-csrk
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 2678930. The openFDA label record carries no UNII and no substance name, and the Drugs@FDA ingredient string is SOTATERCEPT-CSRK, kept as an alias. MeSH has no descriptor for sotatercept (name lookups on 2026-11-18 found only a supplementary concept term), so no MeSH identifier is recorded. RxClass lists the established pharmacologic class Activin Signaling Inhibitor (and the mechanism class Activin Signaling Inhibitors), with sotatercept as the only member, so the record is filed under the class page for activin signaling inhibitors on that evidence; the Winrevair label also calls it an activin signaling inhibitor. The label read is the Merck Sharp & Dohme LLC label for Winrevair, application BLA761363, effective 2026-09-21 in openFDA. This page records the label indication, the mechanism sentence and the class name only: no trial result and no dose is given.
About this drug
- Level
- Substance
- Mechanism
- The label says sotatercept-csrk, a recombinant activin receptor type IIA-Fc fusion protein, is an activin signaling inhibitor.
Claims and evidence
Context Adults with pulmonary arterial hypertension, as described in the US label of Winrevair
- Recipient
- Adult
- Population
- Adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension), as the label states.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Adults, as the label states
- Follow-up
- Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
- Included
- Adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension), as the label states.
- Excluded
- None stated
The US label of Winrevair (sotatercept-csrk, Merck Sharp & Dohme LLC, application BLA761363; the version dated 2026-09-21 in openFDA) describes the medicine as an activin signaling inhibitor. It lists treating adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class, and to reduce the risk of clinical worsening events.
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Winrevair
- Certainty method
- Not assessed
- Limitations
- This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
- Last checked
- 2026-11-18
- Next evidence check due
- Not scheduled
Sources and citations (3)
-
- Locator
- results[0].openfda.application_number[0]
- How it applies
- Application number of the label read, BLA761363.
- Retrieved
- Source effective date
- 2026-09-21
- Source state
- Current
- Version fingerprint
2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260921.
- Retrieved
- Source effective date
- 2026-09-21
- Source state
- Current
- Version fingerprint
2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
- How it applies
- Label passage quoted in the research quote table (Q-K30-SOT-LB-03, Q-K30-SOT-LB-04).
- Retrieved
- Source effective date
- 2026-09-21
- Source state
- Current
- Version fingerprint
2ae8dc93861bb366f22897827fbfcbe419cb6a066bd4cac115bda251d660f536- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (re-fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists pulmonary arterial hypertension in adults, to improve exercise capacity and WHO functional class and to reduce the risk of clinical worsening events, as an indication: Pulmonary arterial hypertension
Applies to Adult Adults with pulmonary arterial hypertension, as described in the US label of Winrevair
The US label of Winrevair (sotatercept-csrk, Merck Sharp & Dohme LLC, application BLA761363; the version dated 2026-09-21 in openFDA) describes the medicine as an activin signaling inhibitor. It lists treating adults with pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension) to improve exercise capacity and WHO functional class, and to reduce the risk of clinical worsening events.Limitations. This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Labels change, and openFDA lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care. Contraindications, warnings, interactions and dosing were not recorded, and no trial result is recorded for the statement.
Record details
- Record id
cardio:sotatercept- Content hash
a261e46371eb17d59249d1e9a48b340439b8a3bf26aea1327c01041ab21fa018